Chronic Inflammatory Demyelinating Polyneuropathy

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a neurological disorder characterized by progressive weakness and impaired sensory function in the arms and legs.

Videos about CIDP

VIEW ALL VIDEOS

CIDP Assessment Tools: INCAT

Jeffrey A. Allen, MD

University of Minnesota

03:32 MIN

CIDP

Learn about the The INCAT scores and variations of them used to evaluate outcome measures for immune-mediated neuropathies

Wear-Off in IVIG and What it Means in Clinical Practice

Jeffrey A. Allen, MD
Carol L. Koski, MD
Thomas Harbo, MD

16:21 MIN

CIDP

Learn about wear-off effects in patients with CIDP, the tools available to monitor them, and the methods to combat them and tailor treatment to the patient.

SELECT A CHAPTER TO VIEW

Introduction

Introduction to wear-off effects

Monitoring wear-off effects

Combating wear-off effects

Conclusion

20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Polyneuropathy (PATH): a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial

Vera Bril, BSc, FRCPC, MD

University of Toronto,Toronto, Canada

15:31 MIN

CIDP

Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP

Subcutaneous Immunoglobulins (SCIg) in Responders to Intravenous Immunoglobulins (IVIg) with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)

Nabil Moumane, MD

Medical Affairs and Pharmacology, CSL Behring

3:00 MIN

CIDP
MMN

Hear why SCIg may be a better option for long-term treatment of patients on Immunoglobulin therapy with difficult venous access.

NOW PLAYING

03:32

CIDP Assessment Tools: INCAT

Learn about the The INCAT scores and variations of them used to evaluate outcome measures for immune-mediated neuropathies

NOW PLAYING

16:21

Wear-Off in IVIG and What it Means in Clinical Practice

Learn about wear-off effects in patients with CIDP, the tools available to monitor them, and the methods to combat them and tailor treatment to the patient.

NOW PLAYING

15:31

20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Poly...

Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP

NOW PLAYING

3:00

Subcutaneous Immunoglobulins (SCIg) in Responders to Intravenous Immunoglobulins (IVIg) with Chronic...

Hear why SCIg may be a better option for long-term treatment of patients on Immunoglobulin therapy with difficult venous access.

Our Experts on CIDP

VIEW ALL EXPERTS

Karissa Gable, MD

Duke University Medical Center in Durham, North Carolina

Karissa Gable, MD

Duke University Medical Center in Durham, North Carolina

CIDP

Dr. Karissa Gable is a Neuromuscular specialist at Duke University Medical Center in Durham, North Carolina.

Vera Bril, BSc, FRCPC, MD

University of Toronto,Toronto, Canada

Vera Bril, BSc, FRCPC, MD

University of Toronto,Toronto, Canada

CIDP

Vera Bril is a Professor of Medicine (Neurology) at the University of Toronto, Director of Neurology at University Health Network and Mount Sinai Hospital and the Krembil Family Chair in Neurology.

Richard A. Lewis, MD

Cedars-Sinai Medical Center, Los Angeles, CA, USA

Richard A. Lewis, MD

Cedars-Sinai Medical Center, Los Angeles, CA, USA

CIDP
GBS
MMN

Richard A. Lewis, MD is Professor of Neurology at Cedars-Sinai Medical Center in Los Angeles, California where he directs the EMG laboratory and co-directs the neuromuscular clinical program.

Jeffrey A. Allen, MD

University of Minnesota